Abstract
Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.
Original language | English |
---|---|
Publication status | Accepted/In press - 12 Mar 2021 |
Event | ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/ |
Conference
Conference | ATS International Conference Committee |
---|---|
Period | 14/05/21 → 19/05/21 |
Internet address |